Article Versions Notes

Velcheti V, Hu X, Li Y, El-Osta H, Pietanza MC, Burke T. Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data. Cancers. 2022; 14(4):1041. https://doi.org/10.3390/cancers14041041

Velcheti, Vamsidhar, Xiaohan Hu, Yeran Li, Hazem El-Osta, M. Catherine Pietanza, and Thomas Burke. 2022. "Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data" Cancers 14, no. 4: 1041. https://doi.org/10.3390/cancers14041041

Velcheti, V., Hu, X., Li, Y., El-Osta, H., Pietanza, M. C., & Burke, T. (2022). Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data. Cancers, 14(4), 1041. https://doi.org/10.3390/cancers14041041